TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The FDA approved Weltruza, a once-monthly subcutaneous formulation of olanzapine for adults with schizophrenia, Teva Pharmaceuticals announced October 9, 2026. The formulation does not require loading doses or post-injection monitoring, though its label still warns about post-injection delirium/sedation syndrome and other risks.
The FDA has approved Weltruza, a once-monthly subcutaneous injection of olanzapine for adults with schizophrenia, Teva Pharmaceuticals announced October 9. Unlike an existing long-acting olanzapine injection, the new formulation does not require loading doses or mandatory post-injection monitoring for delirium or sedation syndrome, a safety concern that has limited use of the older product.
Weltruza is intended to provide a less frequent dosing option than daily oral olanzapine, which has been used for decades. Teva says patients can reach therapeutic blood levels without oral co-treatment, loading doses or booster injections. The injectable will be offered in 318 mg, 425 mg and 531 mg doses, corresponding to oral olanzapine doses of 10 mg, 15 mg and 20 mg, respectively.
The approval was supported by the phase III SOLARIS trial. According to results described in a 2024 Teva press release, each studied dose outperformed placebo on the trial’s primary measure, change in the Positive and Negative Syndrome Scale (PANSS) total score. From baseline to week eight, the mean differences versus placebo ranged from 9.71 to 11.27 points in favor of treatment; all comparisons had P values below 0.001. Teva also reported better results than placebo on clinical global impression and personal and social functioning measures.
No PDSS cases were reported in the trial, according to the source material. However, the product labeling still lists post-injection delirium/sedation syndrome among warnings and precautions. Reported common adverse events included weight gain, sleepiness, headache and constipation. Injection-site reactions included hardening, pain, redness, itching and swelling.
A Monthly Option Without Required Observation
Weltruza adds a monthly formulation of an established schizophrenia medicine for adults whose care may involve daily oral treatment. Less frequent dosing could be useful for patients who have difficulty maintaining a daily medication routine or prefer injections, but the approval alone does not establish that it will improve adherence or outcomes for every patient.
The change in monitoring requirements distinguishes Weltruza from Zyprexa Relprevv, another long-acting olanzapine product. That product carries a risk evaluation and mitigation strategy requiring three hours of observation after each injection because of PDSS risk. Weltruza does not require that observation under the information provided, potentially reducing a practical burden for patients and clinics. Its warning about PDSS remains, so the absence of cases in the trial should not be read as proof that the risk is impossible.
The approval also does not remove the need to weigh olanzapine’s established safety concerns. Like other antipsychotics, its labeling carries a boxed warning about increased mortality in elderly patients with dementia-related psychosis. The label also lists risks including metabolic changes, tardive dyskinesia, neuroleptic malignant syndrome and impaired alertness or motor function.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Navy
Blueair Blue Pure 511i Max Smart Air Purifier
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
As an affiliate, we earn on qualifying purchases.
Olanzapine’s Existing Injection Trade-Off
Olanzapine is an atypical antipsychotic available in oral form for more than 30 years. The source report describes oral olanzapine as the most widely prescribed atypical antipsychotic. Long-acting injections can reduce how often a patient needs a dose, but olanzapine’s existing injectable option has faced a specific obstacle: PDSS monitoring requirements.
PDSS has been associated with agitation, anxiety and confusion in the hours after an injection. The source report notes cases involving people walking into walls or falling asleep in public. Zyprexa Relprevv’s three-hour monitoring requirement addresses that risk. Weltruza’s trial reported no cases, but its label still includes PDSS among the precautions. The reported SOLARIS safety profile was generally consistent with oral olanzapine, alongside reactions tied specifically to injection.
““Adherence continues to be a major barrier to stability, particularly for those who rely on daily oral medications.””
— Christoph Correll, MD, Zucker School of Medicine at Hofstra/Northwell, quoted in Teva’s press release
Trial Findings and Label Risks
The available source material does not provide the full trial publication, detailed participant numbers, or a complete breakdown of results by dose. It also does not specify when Weltruza will become available, its price, insurance coverage or how widely clinicians are likely to prescribe it.
While SOLARIS reported no PDSS cases, the event remains in the product’s warnings and precautions. The supplied information does not quantify the risk of PDSS with Weltruza after approval or explain how clinicians should respond if symptoms occur. Real-world safety and whether monthly dosing changes adherence or clinical outcomes remain to be established through use beyond the trial.
Availability and Real-World Use
The next practical developments are commercial availability and prescribing information, including details on access and cost that were not included in Teva’s announcement as summarized in the source report. Clinicians and patients will also need to review the full label, including the boxed warning and listed risks, when considering whether the injection is appropriate.
As Weltruza enters use, additional real-world information may clarify how often it is prescribed, how patients tolerate injection-site effects and whether the reduced dosing frequency helps people stay on treatment. The FDA approval establishes a new formulation option; it does not resolve those questions.
Key Questions
What did the FDA approve?
The FDA approved Weltruza, a once-monthly subcutaneous olanzapine injection for adults with schizophrenia, according to Teva Pharmaceuticals.
Does Weltruza require three hours of monitoring after injection?
The source report says Weltruza does not require post-injection monitoring for PDSS, unlike Zyprexa Relprevv, which requires three hours of observation. Weltruza’s label still lists PDSS among its warnings and precautions.
What doses will be available?
Teva’s reported dose options are 318 mg, 425 mg and 531 mg, corresponding to oral olanzapine doses of 10 mg, 15 mg and 20 mg, respectively.
What side effects were reported in the trial?
Reported common adverse events included weight gain, sleepiness, headache and constipation. Injection-site effects included hardening, pain, redness, itching and swelling. The labeling also lists other warnings and precautions.
When will Weltruza be available?
The source material does not give an availability date, price or insurance coverage information. Those details remain unclear.
Source: rss
